PODD - Insulet Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
120.18
+0.50 (+0.42%)
As of 12:28PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close119.68
Open120.15
Bid119.83 x 900
Ask120.12 x 1100
Day's Range119.48 - 121.01
52 Week Range70.80 - 124.38
Volume145,448
Avg. Volume586,651
Market Cap7.172B
Beta (3Y Monthly)0.43
PE Ratio (TTM)534.13
EPS (TTM)0.22
Earnings DateAug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est118.38
Trade prices are not sourced from all markets
  • 3 Top Diabetes Stocks to Watch in July
    Motley Fool2 days ago

    3 Top Diabetes Stocks to Watch in July

    These three medtech companies are at the forefront of diabetes care.

  • Insulet (PODD) Soars to 52-Week High, Time to Cash Out?
    Zacks2 days ago

    Insulet (PODD) Soars to 52-Week High, Time to Cash Out?

    Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • MoneyShow15 days ago

    Haemonetics and Insulet- Growth Expert Eyes Medical Devices

    Haemonetics (HAE) is a mid-cap medical technology stock that's on the cusp of breaking out to multi-year highs, notes Mike Cintolo, growth stock specialist and editor of Cabot Top Ten Trader.

  • Business Wire21 days ago

    Insulet to Announce Second Quarter 2019 Financial Results on August 5, 2019

    Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the second quarter of 2019 on August 5, 2019 after the close of the financial markets. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 3268007. Insulet Corporation (PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.

  • Inside the low-key Boston design firm behind everything from sneakers to 'body on a chip'
    American City Business Journals22 days ago

    Inside the low-key Boston design firm behind everything from sneakers to 'body on a chip'

    If you take a walk through EPAM Continuum’s Seaport offices, you’ll spot everything from Reebok Pump sneakers to Pampers, and potentially a peek at a prototype surgical suite of the future. Many of these products were created, at least in part, by the design and consulting firm.

  • Markitlast month

    See what the IHS Markit Score report has to say about Insulet Corp.

    Insulet Corp NASDAQ/NGS:PODDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for PODD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PODD. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PODD had net inflows of $1.72 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Did Hedge Funds Drop The Ball On Insulet Corporation (PODD) ?
    Insider Monkeylast month

    Did Hedge Funds Drop The Ball On Insulet Corporation (PODD) ?

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • Insulet (PODD) Hits 52-Week High on Solid Growth Prospects
    Zackslast month

    Insulet (PODD) Hits 52-Week High on Solid Growth Prospects

    Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.

  • What Are Insulet’s Key Growth Drivers in 2019?
    Market Realistlast month

    What Are Insulet’s Key Growth Drivers in 2019?

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Improving payer accessIn the first quarter, Insulet (PODD) secured coverage for its Omnipod devices for 5 million Medicare and Medicaid members. According to

  • Tandem or Insulet: Who Is Reporting Faster Pump Uptake?
    Market Realistlast month

    Tandem or Insulet: Who Is Reporting Faster Pump Uptake?

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s pump demandIn the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%. The demand rose

  • Tandem Diabetes and Insulet: Comparing Revenue Growth
    Market Realistlast month

    Tandem Diabetes and Insulet: Comparing Revenue Growth

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s revenue trajectoryIn its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue

  • How Analysts Rate Tandem Diabetes Care and Insulet
    Market Realistlast month

    How Analysts Rate Tandem Diabetes Care and Insulet

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?Evolving insulin delivery landscapeUntil the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson

  • Business Wirelast month

    Insulet’s Omnipod® Horizon™ Hybrid Closed-Loop System Improves Glycemic Control in Patients as Young as Two Years Old with Type 1 Diabetes

    Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Insulin Delivery System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, California.

  • Business Wirelast month

    Insulet to Showcase its Recently-Launched Omnipod® DASH™ System and Present Seven Scientific Abstracts at the American Diabetes Association's 79th Scientific Sessions

    No-Cost Personal Diabetes Manager, No Four Year Lock-in Period, and New User Interface Allow for Smooth Transition from Multiple Daily Injections to Pod Therapy

  • Why Diabetes Stock Insulet Soared 27.3% in May
    Motley Foollast month

    Why Diabetes Stock Insulet Soared 27.3% in May

    Shares of the leader in tubeless insulin pump technology continued their upward climb last month.

  • Insulet (PODD) Up 27.8% Since Last Earnings Report: Can It Continue?
    Zacks2 months ago

    Insulet (PODD) Up 27.8% Since Last Earnings Report: Can It Continue?

    Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • How IBD Called The Stock Market Correction Quickly — And Where It May Go From Here
    Investor's Business Daily2 months ago

    How IBD Called The Stock Market Correction Quickly — And Where It May Go From Here

    This week's podcast discussion is all about vertical violations, which can be used to spot a potentially prolonged stock market correction.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PODD earnings conference call or presentation 2-May-19 8:30pm GMT

    Q1 2019 Insulet Corp Earnings Call

  • Business Wire2 months ago

    Insulet to Present at Upcoming Investor Conferences

    Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil

  • GuruFocus.com2 months ago

    Insulet and West Pharma Proven Winners in Growing Wearable Devices Market

    With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.

  • Motley Fool2 months ago

    Insulet and Novocure Are Going Gangbusters

    These two medical-device gems posted record results in the first quarter that send their stocks shooting higher.

  • Motley Fool2 months ago

    2 Winners and 2 Losers in the Med Tech Market This Quarter

    Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.